The recommended dose is 400 mg, once-daily. The duration of treatment should be determined by the severity of the indication or clinical response. The following general recommendations are made:
|
Community-acquired Pneumonia:
|
7-14 days
|
|
Complicated Skin and Skin Structure Infections:
|
7-21 days
|
| Complicated Intra-abdominal Infections: |
5-14 days
|
Therapy may be initial intravenous administration, followed by oral tablet administration when clinically indicated.
The Avelox solution for infusion should be infused intravenously over 60 minutes. It can be administered directly or via a T-tube together with compatible infusion solutions.
The following co-infusions were found to form stable mixtures over a period of 24 hours at room temperature with Avelox solution for infusion, and can therefore be considered as compatible with Avelox solution for infusion:
- Water for injections
- Sodium Chloride 0.9%
- Sodium Chloride 1 Molar
- Glucose 5%
- Glucose 10%
- Glucose 40%
- Xylitol 20%
- Ringer's Solution
- Lactated Ringer's Solution
If Avelox for infusion is to be given with another drug, each drug should be given separately (see also How Supplied for incom- patibilities).
Only clear solutions are to be used.
The Avelox tablet should be swallowed whole with sufficient liquid. Avelox can be taken without regard to meals.
